Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Deadline Alert: Regeneron Pharmaceuticals Inc. REGN

January 25, 2025
Regeneron Pharmaceuticals Inc. (REGN) is facing an important deadline, as investors who have lost money are being urged to contact Glancy Prongay Murray LLP about a securities fraud lawsuit. The lawsuit alleges that the company made false and misleading statements regarding the safety and efficacy of its flagship drug. Investors who suffered losses are recommended to seek legal counsel and potentially join the class action against Regeneron Pharmaceuticals Inc.
If you want to leave a comment, then you need Login or Register





Other data for REGN

Related data

REGNSeptember 5, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Performance  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) has been making waves in the stock market recently, with Evercore ISI maintaining a buy rating and a price target of 750....


REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....


REGNJune 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target  ~1 min.

Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....


REGNJune 5, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 33.76% Profit Margin  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on December 13, 2024, predicted a short direction with a price of 728.18 $. On June 5, 2025, the stock reached the target price of 482....


REGNJune 5, 2025REGENERON PHARMACEUTICALS, INC. Hits Forecast Price Target with a 32.0% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the forecast price target set by QuantWave, resulting in a profit of 32.0%. The forecast signal was issued on December 31, 2024, with a price of $709....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~2 min.

REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 26.25% Profit: QuantWave's Success in Stock Prediction  ~2 min.

REGENERON PHARMACEUTICALS, INC. has recently reached the price target forecast set by QuantWave on June 4, 2025....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. (ticker: REGN) has successfully achieved the price target forecast set by QuantWave, realizing a profit of 27.18%....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....


REGNJanuary 12, 2025Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit  ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, is currently facing a shareholder class action lawsuit....


REGNJanuary 22, 2025Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report  ~1 min.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing a securities class action after suffering a massive value loss of 9 billion following their Q3 2024 earnings report....


REGNJanuary 9, 2025Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report Hagens Berman  ~1 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is facing a securities class action after losing $9 billion in value following its Q3 2024 earnings report....


REGNFebruary 2, 2025Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is currently facing a class action lawsuit filed by investors....


REGNFebruary 6, 2025Regeneron Pharmaceuticals Inc. faces legal action for Securities Law Violations - Seek advice from The Gross Law Firm  ~2 min.

Regeneron Pharmaceuticals Inc., a leading biotechnology company, is currently facing a lawsuit for alleged violations of securities laws....